OMNISCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
OMNISCAN by GE HealthCare is 12. First approved in 2007.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMNISCAN (gadodiamide) is a paramagnetic contrast agent administered intravenously for magnetic resonance imaging (MRI) to enhance visualization of normal and pathologic tissues. It works by shortening T1 and T2 relaxation times in tissues, increasing signal intensity and enabling detection of lesions such as neoplasms, abscesses, and infarcts where the blood-brain barrier is disrupted. The drug is eliminated primarily through renal glomerular filtration with a 78-minute elimination half-life.
LOE Approaching
As LOE approaches, the brand team will likely consolidate and shift focus toward lifecycle extension strategies and market defense against generic/biosimilar entrants.
Mechanism of Action
12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These variations occur due to: changes in proton density; alteration of the spin-lattice or longitudinal relaxation time (T 1 );…
Worked on OMNISCAN at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.